Magrilan (Fluoxetine Hydrochloride)

Fluoxetine Hydrochloride is an SSRI that modulates serotonergic pathways to treat several psychiatric disorders.

• Major depressive disorder: reduces depressive symptoms and improves overall mood.
• Obsessive‑compulsive disorder: lessens compulsive thoughts and repetitive behaviors.
• Panic disorder: decreases frequency and intensity of panic attacks.
• Bulimia nervosa: helps control binge‑eating episodes and associated urges.
• Premenstrual dysphoric disorder: alleviates mood swings and physical symptoms linked to the menstrual cycle.

• Fluoxetine selectively inhibits the serotonin transporter (SERT) on presynaptic neurons, blocking reuptake of serotonin (5‑HT) from the synaptic cleft. This increases extracellular serotonin concentrations, enhancing serotonergic neurotransmission throughout central nervous system pathways that regulate mood, anxiety, and appetite. The drug’s high affinity for SERT and minimal activity at other receptors underlies its therapeutic profile as an antidepressant.

Fluoxetine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Headache
• Insomnia
• Dry mouth

Serious or Rare Side Effects

• Serotonin syndrome
• Suicidal thoughts or behavior
• Severe allergic reaction (anaphylaxis)
• Hyponatremia

When prescribing or dispensing Magrilan, consider the following precautions.

• Assess psychiatric history: evaluate for depression severity and suicidal risk before initiating therapy.
• Monitor for suicidal ideation: especially during the first few weeks of treatment or dosage changes.
• Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms.
• Use caution in hepatic impairment: dose adjustment may be required in patients with liver dysfunction.
• Contraindicated with MAO inhibitors: ensure a minimum 14‑day washout period when switching.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Fluoxetine can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; maintain at least a 14‑day washout period.
• Pimozide or thioridazine: may cause cardiac arrhythmias when combined.
• Linezolid or other serotonergic antibiotics: increase serotonin levels, raising syndrome risk.

Moderate Interactions (Monitor Closely)

• NSAIDs and anticoagulants: may increase bleeding tendency.
• CYP2D6 inhibitors (e.g., quinidine): can raise fluoxetine plasma levels.
• Alcohol: may exacerbate CNS side effects such as dizziness or sedation.